NCT01099436

Neo-Adjuvant Chemotherapy (TAC) With or Without Zoledronic Acid in Treating HER2-negative Breast Cancer Patients

A Phase III Randomized Trial With NEOadjuvant Chemotherapy (TAC) With or Without ZOledronic Acid for Patients With HER2- Negative Large Resectable or Locally Advanced Breast Cancer(NEO-ZOTAC)

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 250 (actual)
• Sponsor: Borstkanker Onderzoek Groep · Network
• Sex: Female
• Age: 18 Years – 120 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, docetaxel, and zoledronic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known whether combination chemotherapy is more effective when given together with zoledronic acid in treating patients with breast cancer. PURPOSE: This randomized phase III trial is studying giving doxorubicin hydrochloride together with cyclophosphamide and docetaxel to see how well it works with or without zoledronic acid in treating patients with large resectable or locally advanced breast cancer.

Detailed description

OBJECTIVES: Primary * To determine the value of neoadjuvant chemotherapy comprising doxorubicin hydrochloride, cyclophosphamide, and docetaxel with or without zoledronic acid in patients with HER2-negative large resectable or locally advanced breast cancer. Secondary * To correlate clinical response with pathological responses in both treatment arms. * To evaluate the disease-free survival and overall survival of patients treated with this regimen. * To evaluate the safety and tolerability of adding zoledronic acid to neoadjuvant chemotherapy. * To evaluate heterogeneity of the ER/PR and HER2 measurement in core biopsy and the surgical specimen. OUTLINE: Patients are randomized between 2 treatment arms. * Arm I: Patients receive doxorubicin hydrochloride IV, cyclophosphamide IV, and docetaxel IV on day 1. Patients also receive zoledronic acid IV over 15 minutes on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. * Arm II: Patients receive doxorubicin hydrochloride IV, cyclophosphamide IV, and docetaxel IV as in arm I. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.

Conditions

• Breast Cancer

Interventions

Type	Name	Description
DRUG	cyclophosphamide
DRUG	docetaxel
DRUG	doxorubicin hydrochloride
DRUG	zoledronic acid
PROCEDURE	neoadjuvant therapy

Timeline

• Start date: 2010-04-01
• Primary completion: 2012-04-01
• Completion: 2013-09-01
• First posted: 2010-04-07
• Last updated: 2020-01-21

Locations

1 site across 1 country: Netherlands